KYMR
Kymera Therapeutics, Inc.
Stock
$107.39−2.73 (−2.48%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$237M | −$233M | −$195M | −$103M | −$153M | −$129M | $88M | $18M |
| Capital expenditures | $1.2M | $1.4M | $13M | $34M | $2.8M | $1.6M | $9.1M | $532K |
| Free cash flow | −$238M | −$234M | −$207M | −$137M | −$156M | −$131M | $79M | $17M |
| Stock-based compensation | $65M | $60M | $55M | $43M | $35M | $25M | $5.2M | $1.2M |
| Free cash flow margin | −226.6% | −597.6% | −440.5% | −174.7% | −333.0% | −179.2% | 232.2% | 592.1% |